Regulatory

Regulatory  ·  Weekly Digest 26 Apr to 02 May 2025
OBI Pharma announces U.S. FDA clearance of IND application for a Phase 1/2 study of OBI-902, a Trop-2 targeting ADC

Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: OBI Pharma announces U.S. FDA clearance of IND application for a Phase 1/2 study of OBI-902, a Trop-2 targeting ADC OBI Pharma received U.S. FDA clearance to […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 26 Apr to 02 May 2025
The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089

Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089 Hansoh Pharmaceuticals B7-H4-targeted ADC, HS-20089, has been granted BTD by China’s National Medical Products Administration (NMPA) […]

by Sandhya Ramalingam

Continue Reading